Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 11,175 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Arm 3 Clear all
Not listed Phase 2 Interventional

Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer

NCT00499525
View directory record Official record
Conditions
Breast Cancer
Interventions
paclitaxel, sorafenib tosylate, placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
43
States / cities
Muscle Shoals, Alabama • Fayetteville, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 20, 2026, 1:47 AM EDT
Completed Not applicable Interventional

An Intervention to Promote Use of Smoking Cessation Resources Among Adults Using Community Food Pantries

NCT05273450
View directory record Official record
Conditions
Smoking Cessation, Food Insecurity
Interventions
Quitline Information with Reinforcement
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
21 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 20, 2026, 1:47 AM EDT
Active, not recruiting Phase 3 Interventional

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01863550
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Bortezomib, Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Quality-of-Life Assessment
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,087 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2034
U.S. locations
909
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Hot Springs, Arkansas + 551 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

NCT02921997
View directory record Official record
Conditions
Avian Influenza, H1N1 Influenza, Influenza
Interventions
AS03, Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203, Monovalent influenza A/H7N9 virus vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 20, 2026, 1:47 AM EDT
Recruiting Not applicable Interventional

Employment Support After Hematopoietic Stem Cell Transplantation

NCT06494423
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
Work Support (WorkS)
Behavioral
Lead sponsor
MGH Institute of Health Professions
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 20, 2026, 1:47 AM EDT
Completed No phase listed Observational Results available

Remote Assessment of Physical Function

NCT04339959
View directory record Official record
Conditions
Cancer Survivors
Interventions
Remote Assessment of Physical Function with Direct Observation, Remote Assessment of Physical Function
Other
Lead sponsor
University of New Mexico
Other
Eligibility
60 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 20, 2026, 1:47 AM EDT
Terminated Phase 3 Interventional Results available

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

NCT00004859
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, thalidomide, radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
235
States / cities
Fort Smith, Arkansas • Modesto, California • Salinas, California + 168 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 20, 2026, 1:47 AM EDT
Recruiting Not applicable Interventional

Mobile Health Program for Post-Preeclampsia Hypertension

NCT07599579
View directory record Official record
Conditions
Hypertension (HTN), Preeclampsia, Hypertensive Disorders of Pregnancy (HDP)
Interventions
Coaching application, Home-based blood pressure monitoring, WebMD
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 20, 2026, 1:47 AM EDT
Active, not recruiting Phase 3 Interventional

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915
View directory record Official record
Conditions
Sjogrens Syndrome
Interventions
Ianalumab (VAY736), Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
32
States / cities
Fullerton, California • La Palma, California • Van Nuys, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 1:47 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients

NCT01064791
View directory record Official record
Conditions
Renal Transplantation
Interventions
sotrastaurin (Dose 1) + tacrolimus + standard of care medications, sotrastaurin (Dose 2) + tacrolimus + standard of care medications, sotrastaurin (Dose 3) + tacrolimus + standard of care medications, mycophenolic acid + tacrolimus + standard of care medications
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
7
States / cities
Birmingham, Alabama • Aurora, Colorado • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 20, 2026, 1:47 AM EDT
Active, not recruiting Not applicable Interventional

Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening and Enhanced Navigation on Care Delivery for Patients With Breast Cancer

NCT06019988
View directory record Official record
Conditions
Breast Cancer, Social Determinants of Health (SDOH)
Interventions
Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 20, 2026, 1:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study

NCT00736255
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Nicotine Dependence
Interventions
Transdermal Nicotine Patch, Lis-dexamphetamine (Vyvanse), Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 20, 2026, 1:47 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

NCT04988555
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
Enzomenib, azoles, Venetoclax, Gilteritinib, Azacitidine (AZA), Intensive chemotherapy with 7 + 3
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
33
States / cities
Newport Beach, California • Palo Alto, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 20, 2026, 1:47 AM EDT
Recruiting Phase 3 Interventional

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

NCT07220915
View directory record Official record
Conditions
Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
Interventions
Panzyga, 10% Intravenous Solution, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Glendale, Arizona • Mesa, Arizona • Scottsdale, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 1:47 AM EDT
Completed Phase 2 Interventional

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

NCT01915589
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Refametinib (BAY86-9766)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Miami, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 20, 2026, 1:47 AM EDT
Not yet recruiting Phase 3 Interventional

iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma

NCT07815574
View directory record Official record
Conditions
Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
Interventions
iSCIB1+, Nivolumab & Ipilimumab, Placebo
Biological · Drug · Other
Lead sponsor
Scancell Ltd
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 20, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

NCT02741323
View directory record Official record
Conditions
HIV Infections, Kidney Diseases
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 20, 2026, 1:47 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

NCT02187003
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Rivipansel, Placebo
Drug · Other
Lead sponsor
Biossil Inc.
Industry
Eligibility
6 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
126
States / cities
Mobile, Alabama • Little Rock, Arkansas • Oakland, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 20, 2026, 1:47 AM EDT
Completed Not applicable Interventional Results available

Mantram Repetition to Manage PTSD in Veterans

NCT00120627
View directory record Official record
Conditions
Stress Disorders, Post Traumatic
Interventions
Mantram Repetition Program (MRP) plus Usual Care, Usual care consisting of medication and case management
Behavioral · Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 20, 2026, 1:47 AM EDT
Recruiting Phase 2 Interventional

Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

NCT01419561
View directory record Official record
Conditions
KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8
Interventions
Zidovudine, Liposomal Doxorubicin, Valganiclovir, Rituximab, Standard Therapies, Cohort 1
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 1:47 AM EDT
Suspended Phase 1 Interventional

First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

NCT04711161
View directory record Official record
Conditions
Ovarian Tumors
Interventions
GRN-300, Paclitaxel
Drug
Lead sponsor
Green3Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 20, 2026, 1:47 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

NCT02143648
View directory record Official record
Conditions
Uremic Pruritus, Pruritus
Interventions
nalbuphine HCl ER tablets 60 mg BID, nalbuphine HCl ER tablets 120mg BID, Placebo tablets BID
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 20, 2026, 1:47 AM EDT
Completed Not applicable Interventional Results available

Pelvic Floor Physical Therapy vs Standard Care in Transgender Women Undergoing Vaginoplasty for Gender Affirmation

NCT05690555
View directory record Official record
Conditions
Pelvic Floor Disorders
Interventions
Preoperative and Postoperative Pelvic Floor Physical Therapy (PFPT), No Pelvic Floor Physical Therapy (PFPT), Postoperative PFPT
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 20, 2026, 1:47 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

NCT04810078
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Nivolumab and rHuPH20, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Buffalo, New York • West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 20, 2026, 1:47 AM EDT